Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02614131 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT02614131 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 50 participants.
The verdict
NCT02614131, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who are healthy, those who have mild cognitive impairment due to Alzheimer's Disease (AD), and those with mild-to-moderate AD. The study will measure how much LY2599666 gets into the bloodstream and how long it takes the body to get rid of it. It will also evaluate how LY2599666 affects the body. The study has three parts. Part A will last about 2 months. Parts B and C will each last about 23 weeks. Participants may only enroll in one part.
Interventions
- DRUG Placebo IV
- DRUG Placebo SC
- DRUG Solanezumab
- DRUG LY2599666
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02614131
The ClinicalTrials.gov registry entry for NCT02614131 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo IV is the first listed.
NCT02614131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02614131 about?
NCT02614131 is a clinical study titled "A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)". The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who are healthy, those who have mild cognitive impairment due to Alzheimer's Disease (AD), and those with mild-to-moderate AD. The study will measure h...
What is the current status of trial NCT02614131?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2015-12. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02614131?
The interventions under investigation include: Placebo IV (DRUG), Placebo SC (DRUG), Solanezumab (DRUG), LY2599666 (DRUG).
Who is sponsoring clinical trial NCT02614131?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.